FOLH1 and neoplasm: Previously used mouse models demonstrated enhanced potency of CAR T-cells by the co-expression of dominant-negative TGFß in PSMA-directed CAR T-cells compared to unmodified CAR T-cells with increased immune responses, long-term in-vivo persistence and tumor eradication [75].